Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy (Front. Pharmacol., (2023), 14, 1150270, 10.3389/fphar.2023.1150270)

Naveen Kumar Velayutham, Tamilanban Thamaraikani, Shadma Wahab, Mohammad Khalid, Gobinath Ramachawolran, Shahabe Saquib Abullais, Ling Shing Wong, Mahendran Sekar, Siew Hua Gan, Angel Jemima Ebenezer, Mrinalini Ravikumar, Vetriselvan Subramaniyan, Nur Najihah Izzati Mat Rani, Yuan Seng Wu, Srikanth Jeyabalan

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

In the published article, there was an error in the Article Title. Instead of “Stylopine: A potential natural metabolite to activate vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy,” it should be “Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy.” Additionally, there was an error in the Conflict of Interest statement. The original statement omitted the declaration for commercial affiliations. The correct Conflict of Interest statement appears below. Author AE was employed by Trichy Research Institute of Biotechnology Pvt Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number1343756
Number of pages2
JournalFrontiers in Pharmacology
Volume15
DOIs
Publication statusPublished - 2024

Keywords

  • benzylisoquinoline alkaloids
  • MG-63
  • osteosarcoma
  • stylopine
  • VEGFR2

Cite this